Equities research analysts forecast that Regenxbio Inc (NASDAQ:RGNX) will post sales of $10.00 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Regenxbio’s earnings. Regenxbio posted sales of $2.04 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 390.2%. The company is expected to issue its next quarterly earnings results on Tuesday, March 5th.
On average, analysts expect that Regenxbio will report full-year sales of $210.06 million for the current year, with estimates ranging from $187.73 million to $232.40 million. For the next fiscal year, analysts anticipate that the business will report sales of $22.71 million, with estimates ranging from $13.70 million to $33.93 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for Regenxbio.
Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.30. Regenxbio had a return on equity of 22.52% and a net margin of 44.30%. The company had revenue of $5.31 million during the quarter.
A number of brokerages recently commented on RGNX. ValuEngine lowered Regenxbio from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 11th. BidaskClub lowered Regenxbio from a “buy” rating to a “hold” rating in a research note on Friday, October 5th. Barclays increased their price target on Regenxbio from $48.00 to $83.00 and gave the company an “overweight” rating in a research note on Monday, August 13th. Raymond James set a $96.00 price target on Regenxbio and gave the company a “buy” rating in a research note on Thursday, November 8th. Finally, Bank of America increased their price target on Regenxbio from $76.00 to $84.00 and gave the company a “neutral” rating in a research note on Thursday, November 8th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $77.81.
In other Regenxbio news, Director Luke M. Beshar sold 12,784 shares of the company’s stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $65.00, for a total transaction of $830,960.00. Following the sale, the director now directly owns 12,784 shares in the company, valued at $830,960. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Patrick J. Christmas sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, October 18th. The shares were sold at an average price of $61.78, for a total value of $308,900.00. Following the sale, the senior vice president now owns 22,669 shares in the company, valued at $1,400,490.82. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 448,954 shares of company stock worth $28,902,916. Company insiders own 16.90% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Riverhead Capital Management LLC raised its holdings in shares of Regenxbio by 137.5% in the third quarter. Riverhead Capital Management LLC now owns 1,900 shares of the biotechnology company’s stock worth $143,000 after buying an additional 1,100 shares during the period. Meadow Creek Investment Management LLC purchased a new stake in shares of Regenxbio in the second quarter worth approximately $141,000. Russell Investments Group Ltd. purchased a new stake in shares of Regenxbio in the second quarter worth approximately $157,000. Glen Harbor Capital Management LLC purchased a new stake in shares of Regenxbio in the second quarter worth approximately $171,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Regenxbio in the second quarter worth approximately $179,000. Institutional investors and hedge funds own 79.08% of the company’s stock.
Shares of Regenxbio stock opened at $52.44 on Friday. Regenxbio has a 12 month low of $23.25 and a 12 month high of $85.10. The company has a market cap of $1.96 billion, a P/E ratio of -21.40, a PEG ratio of 8.05 and a beta of -0.53.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Featured Story: How the Consumer Price Index (CPI) is calculated?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.